In brief
- A narrative review in the Journal of Clinical Oncology treats EGFR P-loop/αC-helix compressing (PACC) mutations and exon 20 insertions as subsets distinct from classical sensitising mutations.
- For PACC variants such as G719X, S768I, E709X and L747X, the authors report that second-generation TKIs such as afatinib provide the most consistent activity.
- Compound mutations pairing a classical alteration with a PACC variant often derive greater benefit from third-generation TKIs, including osimertinib.
- In exon 20 insertion disease, amivantamab, sunvozertinib, zipalertinib and firmonertinib have shown clinically meaningful activity, and WU-KONG28 established first-line superiority of sunvozertinib over platinum-pemetrexed.
- Resistance in both subsets is heterogeneous, spanning on-target mutations such as C797S and E709K and bypass pathways including MET.
A structure-function classification defines two separate subsets
The review is built on a classification that sorts kinase domain EGFR alterations by structure and function, and places PACC mutations and exon 20 insertions in groups of their own. The authors treat the two as established subgroups, set apart from classical mutations both by their structure and by how they respond to the TKIs now available.
The abstract describes the work as a narrative review. It gives no search strategy, no count of the studies considered and no pooled estimate, so its treatment statements summarise the evidence the authors chose to discuss.
Afatinib for PACC variants, osimertinib for compound mutations
For single PACC variants, including G719X, S768I, E709X and L747X, the authors find the most consistent activity with second-generation TKIs such as afatinib. Tumours in which a classical alteration occurs together with a PACC variant behave differently: these compound mutations often derive greater benefit from third-generation TKIs, osimertinib among them.
Mutant-selective inhibitors are the newer development in this subset. Firmonertinib and enozertinib are being explored as dedicated options for PACC mutations, and the abstract gives no response rates or survival figures for either.
WU-KONG28 placed sunvozertinib ahead of platinum-pemetrexed in first-line exon 20 disease
For exon 20 insertions, the review lists amivantamab and three mutant-selective TKIs, sunvozertinib, zipalertinib and firmonertinib, as agents with clinically meaningful activity. Of these, sunvozertinib is the one with a first-line comparison cited in the abstract: the authors credit WU-KONG28 with establishing its superiority over platinum-pemetrexed chemotherapy.
Firmonertinib appears on both lists, under investigation for PACC mutations and with reported activity against exon 20 insertions. The abstract does not report the WU-KONG28 effect size.
“EGFR PACC and ex20ins are established subgroups of kinase domain mutations, distinct from classical mutations, due to structure and responsiveness to available TKIs.”Monaca et al., Journal of Clinical Oncology (2026)
Resistance spans C797S, E709K and MET bypass signalling
In both subsets, the authors describe resistance as heterogeneous. It includes on-target EGFR mutations, of which C797S and E709K are named, as well as MET and other bypass track pathways.
Treatment sequencing is one of the stated aims of the review, but the abstract does not set out a recommended order for afatinib, osimertinib, amivantamab and the newer selective inhibitors.
Sources
- Journal of Clinical Oncology. P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR –Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape (2026-09-14). doi.org
Featuring Lung Summit faculty
This study was co-authored by Lung Summit faculty Alfredo Addeo and Xiuning Le.
This article was produced independently by the Lung Summit editorial team, without industry funding or input.
